Using different cancer models, we have already validated Rac1 as a target and 1A-116 as a small molecule to be potentially exploited in therapeutics schemes (Cardama et al., 2014a; Cabrera et al., 2017; Gonzalez et al., 2017). Here, RAC1 is linked to cancer.